SCHEMBL6719225

SCHEMBL6719225

O=C(COc1c(Cl)cc(Cl)c2cccnc12)c1c2n(c3ccccc13)CCNCC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.51
HTR2A P28223 7/20 0.50
HTR2C P28335 7/20 0.50
ALDH1A1 P00352 5/20 0.44
NPSR1 Q6W5P4 5/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 5/20 0.41
HTT P42858 6/20 0.40
MAPT P10636 5/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
LMNA P02545 4/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
RAB9A P51151 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
HDAC6 Q9UBN7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6718547 0.88 KDM4E (0.52) HTR2AHTR2CALDH1A1MEN1KMT2A
SCHEMBL6711349 0.87 HTR2A (0.51) HTR2AHTR2CALDH1A1NPSR1MEN1
SCHEMBL6713598 0.86 HTR2A (0.50) HTR2AHTR2CALDH1A1KDM4EHTT
SCHEMBL6714275 0.86 ALDH1A1 (0.52) HTR2AHTR2CALDH1A1NPSR1MEN1
SCHEMBL6718875 0.83 HTR2A (0.54) HTR2AHTR2C
SCHEMBL6711977 0.82 HTR2A (0.61) HTR2AHTR2CKDM4EL3MBTL1
SCHEMBL6713514 0.81 HTR2A (0.53) HTR2AHTR2CALDH1A1NPSR1KDM4E
SCHEMBL6711312 0.80 HTR2A (0.58) HTR2AHTR2CALDH1A1MEN1KMT2A
SCHEMBL6718491 0.80 HTR2A (0.51) HTR2AHTR2C
SCHEMBL6714451 0.79 HTR2A (0.46) HTR2AHTR2CALDH1A1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US claimed
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
EP-1328525-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-A]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-23 EP disclosed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US disclosed
WO-2001072752-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E HIF1A 2525/4885HTR2A 18/4885HTR2C 7/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 HIF1A 3210/4885HTR2A 1403/4885HTR2C 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.